Biogen Reports Progress In Late-Stage Programs, Plus Some Bumps In The Road
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen Idec reported steady progress in the clinic for four late-stage programs, including hemophilia. Recent bumps include a three-month delay for the MS product BG-12, but nothing that would derail its Phase III pipeline.